Biomarkers and beyond in lung cancer

Oral Presentation
Chairs: R. Huber (Munich, Germany), J. Domagala-Kulawik (Warszawa, Poland)

Introduction R. Huber (Munich, Germany), J. Domagala-Kulawik (Warszawa, Poland)
Quantitative proteomics indicates radical removal of non-small cell lung cancer and predicts outcome E. Bodén (Lund, Sweden), J. Andreasson (Lund, Sweden), G. Hirdman (Lund, Sweden), O. Hallgren (Lund, Sweden), F. Olm (Lund, Sweden), S. Lindstedt (Lund, Sweden)
Prophylactic use of mini tracheostomy in patients with comorbidities undergoing lung resection I. Karampinis (Athens, Greece), G. Hardavella (Athens, Greece), A. Katsipoulakis (Athens, Greece), N. Anastasiou (Athens, Greece)
Relationship between clinicopathologic characteristics and spread through air spaces in resected lung adenocarcinoma and squamous cell carcinoma cases T. Tezvergil (Ankara, Turkey), U. Yilmaz (Ankara, Turkey)
Subtype-specific transcription factors are clinically relevant and show distinct therapeutic vulnerabilities in human small cell lung cancer C. Lang (Vienna, Austria), Z. Megyesfalvi (Budapest, Hungary), B. Szeitz (Budapest, Hungary), A. Lantos (Budapest, Hungary), N. Woldmar (Lund, Sweden), Z. Valko (budapest, Hungary), A. Schwendenwein (Vienna, Austria), F. Oberndorfer (Vienna, Austria), N. Barany (Budapest, Hungary), S. Paku (Budapest, Hungary), V. Laszlo (Vienna, Austria), H. Kiss (Budapest, Hungary), E. Bugyik (Budapest, Hungary), B. Ferencz (Budapest, Hungary), K. Dezso (Budapest, Hungary), Z. Lohinai (Budapest, Hungary), J. Moldvay (Budapest, Hungary), J. Fillinger (Budapest, Hungary), G. Galffy (Budapest, Hungary), C. Rivard (Colorado, United States), F. Hirsch (Colorado, United States), L. Brcic (Graz, Austria), H. Popper (Graz, Austria), I. Kern (Golnik, Slovenia), M. Kovacevic (Golnik, Slovenia), J. Skarda (Olomouc / Ostrava, Czech Republic), M. Mittak (Olomouc / Ostrava, Czech Republic), A. Szasz (Budapest, Hungary), L. Pizzatti (Rio de Janeiro, Brazil), K. Bogos (Budapest, Hungary), M. Hoda (Vienna, Austria), K. Hoetzenecker (Vienna, Austria), G. Marko-Varga (Lund, Sweden), P. Horvatovics (Groningner, Netherlands), F. Renyi-Vamos (Budapest, Hungary), T. Klikovits (Vienna, Austria), K. Schelch (Vienna, Austria), M. Rezeli (Lund, Sweden), B. Döme (Budapest, Hungary)
IGFBP3 inhibits tumour growth and invasion of H1299 lung cancer cells and leads to improved survival in patients with lung cancer A. Frille (Leipzig, Germany), H. Kuhn (Leipzig, Germany), M. Petersen (Leipzig, Germany), J. Meyer (Leipzig, Germany), L. Hofmann (Leipzig, Germany), A. Gläser (Leipzig, Germany), S. Taubenheim (Leipzig, Germany), S. Krämer (Leipzig, Germany), J. Broschewitz (Bremen, Germany), M. Von Laffert (Leipzig, Germany), H. Wirtz (Leipzig, Germany)
Extracellular vesicles derived from lung cancer cells exposed to intermittent hypoxia promote M2 macrophage polarization through miR-20a-5p/PTEN/Akt pathway y. liu (GuangZhou, China), G. Xu (GuangZhou, China), C. Feng (GuangZhou, China), Y. Chen (GuangZhou, China), H. Sun (GuangZhou, China), F. Liu (GuangZhou, China), W. Ma (GuangZhou, China)
On-chip human microvasculature assay to study extravasation dynamics of lung cancer cells S. Zeinali (Bern, Switzerland), K. Rechberger (Bern, Switzerland), C. Dubey (Bern, Switzerland), R. Gashi (Bern, Switzerland), T. Marti (Bern, Switzerland), P. Dorn (Bern, Switzerland), O. Guenat (Bern, Switzerland)